Knoll Capital Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Knoll Capital Management’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-600,000	Closed	-$12.9M	–	39
2025 Q4	$12.9M	Hold	600,000	–	–	5.93%	4
2025 Q3	$9.16M	Hold	600,000	–	–	4.91%	7
2025 Q2	$5.31M	Hold	600,000	–	–	3.78%	9
2025 Q1	$4.7M	Hold	600,000	–	–	3.06%	10
2024 Q4	$6.31M	Hold	600,000	–	–	4.06%	8
2024 Q3	$7.87M	Hold	600,000	–	–	3.65%	5
2024 Q2	$8.44M	Hold	600,000	–	–	5.68%	4
2024 Q1	$10.1M	Hold	600,000	–	–	6.3%	4
2023 Q4	$8.47M	Hold	600,000	–	–	7.02%	4
2023 Q3	$6.18M	Buy	600,000 +100,000	+20%	+$1.34M	6.42%	4
2023 Q2	$8.24M	Buy	+500,000	New	+$6.5M	9.99%	3
2023 Q1	–	Sell	-150,000	Closed	-$1.23M	–	27
2022 Q4	$1.07M	Buy	+150,000	New	+$1.05M	2.42%	13

Other funds holding AVDL

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Knoll Capital Management's AVDL Position: Q1 2026 in Review

Knoll Capital Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 600,000 shares — an estimated $12.9M sold.

Knoll Capital Management first reported a position in AVDL in Q4 2022 and held it in 12 quarters. The position peaked at $12.9M in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

Knoll Capital Management reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Knoll Capital Management sold 600,000 Avadel Pharmaceuticals shares in Q1 2026, an estimated $12.9M.
Knoll Capital Management first reported a position in Avadel Pharmaceuticals in Q4 2022 and held it in 12 quarters.
Knoll Capital Management's Avadel Pharmaceuticals position peaked at $12.9M in Q4 2025.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Knoll Capital Management's 13F filing for Q1 2026, filed 15 May 2026.